Last reviewed · How we verify
NCT04659512
Recurrent Neovascular Age-related Macular Degeneration After Therapy Suspension
trial in Age-related Macular Degeneration in 105 participants. Completed in 6 June 2020.
28 February 2019
Quick facts
| Lead sponsor | St. Erik Eye Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 105 |
| Start date | 1 October 2017 |
| Primary completion | 28 February 2019 |
| Estimated completion | 6 June 2020 |
| Sites | 1 location across Sweden |
Conditions studied
- Age-related Macular Degeneration — all drugs for Age-related Macular Degeneration →
Sponsor
St. Erik Eye Hospital
Who can join
55 and older, any sex, with Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate prospectively the recurrence rate of active macular neovascularization (MNV) and the visual outcome in patients with nAMD previously on a Treat and Extend regimen where treatment has been discontinued due to disease stability.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04659512
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06961370 — A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO76693 · Phase 1 · recruiting
- NCT06458595 — Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) · Phase 1, PHASE2 · recruiting
- NCT03848663 — Visual Remapping to Aid Reading With Field Loss · NA · recruiting
- NCT04735263 — Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD · Phase 2 · recruiting
- NCT03752840 — Village-Integrated Eye Worker Trial II · NA · recruiting
Other St. Erik Eye Hospital trials
Trials by the same sponsor.
- NCT06717139 — Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD · active not recruiting
- NCT04888156 — Impact of Self-tonometry on Glaucoma Treatment Decision. · completed
- NCT04911387 — iCare® Home vs Goldmann Applanation Tonometry · completed
- NCT04150263 — Modification of Scleral Suture Fixation of Dislocated IOL · NA · completed
- NCT03709745 — Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04659512 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Erik Eye Hospital
- Last refreshed: 10 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659512.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing